Obstructive sleep apnea and cognitive impairment: Addressing the blood-brain barrier

Sleep Medicine Reviews

Volumn 18, Issue 1, 2014, Pages 35-48

  Lim, Diane C ^a   Pack, Allan I ^a  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

Angiogenesis; Blood brain barrier; Blood brain barrier transporters; Chronic inflammation; Cognitive impairment; Hif1 ; Hif2 ; Leak; Microvessel permeability; Obstructive sleep apnea; Oxidative stress; Oxygen sensor; Peroxisome proliferator activated receptor; Pore

Indexed keywords

DELTA LIKE LIGAND 4; HYPOXIA INDUCIBLE FACTOR 1ALPHA; HYPOXIA INDUCIBLE FACTOR 2ALPHA; PROTEIN; REACTIVE OXYGEN METABOLITE; UNCLASSIFIED DRUG; VASCULOTROPIN;

ANGIOGENESIS; ASTROCYTE; BLOOD BRAIN BARRIER; BLOOD VESSEL PERMEABILITY; CHRONIC INTERMITTENT HYPOXIA; COGNITIVE DEFECT; ENDOTHELIUM CELL; HOMEOSTASIS; HUMAN; INFLAMMATION; MICROVASCULATURE; NERVE CELL PLASTICITY; NUTRIENT UPTAKE; OXIDATIVE STRESS; OXYGEN CONSUMPTION; PERICYTE; PROTEIN EXPRESSION; REVIEW; SLEEP DISORDERED BREATHING; TIGHT JUNCTION;

ANGIOGENESIS; BLOOD-BRAIN BARRIER; BLOOD-BRAIN BARRIER TRANSPORTERS; CHRONIC INFLAMMATION; COGNITIVE IMPAIRMENT; HIF1Α; HIF2Α; LEAK; MICROVESSEL PERMEABILITY; OBSTRUCTIVE SLEEP APNEA; OXIDATIVE STRESS; OXYGEN SENSOR; PEROXISOME PROLIFERATOR-ACTIVATED RECEPTOR; PORE;

ANOXIA; BLOOD-BRAIN BARRIER; COGNITION DISORDERS; HUMANS; SLEEP APNEA, OBSTRUCTIVE;

EID: 84890176617     PISSN: 10870792     EISSN: 15322955     Source Type: Journal    
DOI: 10.1016/j.smrv.2012.12.003     Document Type: Review

References (176)

1. Young T., Palta M., Dempsey J., Skatrud J., Weber S., Badr S. The occurrence of sleep-disordered breathing among middle-aged adults. NEngl J Med 1993, 328:1230-1235.
2. Young T., Peppard P.E., Taheri S. Excess weight and sleep-disordered breathing. JAppl Physiol 2005, 99:1592-1599.
3. Tishler P.V., Larkin E.K., Schluchter M.D., Redline S. Incidence of sleep-disordered breathing in an urban adult population: the relative importance of risk factors in the development of sleep-disordered breathing. JAMA 2003, 289:2230-2237.
4. Newman A.B., Foster G., Givelber R., Nieto F.J., Redline S., Young T. Progression and regression of sleep-disordered breathing with changes in weight: the sleep heart health study. Arch Intern Med 2005, 165:2408-2413.
5. Lee W., Nagubadi S., Kryger M.H., Mokhlesi B. Epidemiology of obstructive sleep apnea: a population-based perspective. Expert Rev Respir Med 2008, 2:349-364.
6. Beccuti G., Pannain S. Sleep and obesity. Curr Opin Clin Nutr Metab Care 2011, 14:402-412.
7. Pack A.I., Gislason T. Obstructive sleep apnea and cardiovascular disease: a perspective and future directions. Prog Cardiovasc Dis 2009, 51:434-451.
8. Pamidi S., Aronsohn R.S., Tasali E. Obstructive sleep apnea: role in the risk and severity of diabetes. Best Pract Res Clin Endocrinol Metab 2010, 24:703-715.
9. Musso G., Olivetti C., Cassader M., Gambino R. Obstructive sleep apnea-hypopnea syndrome and nonalcoholic fatty liver disease: emerging evidence and mechanisms. Semin Liver Dis 2012, 32:49-64.
10. Nieto F.J., Peppard P.E., Young T., Finn L., Hla K.M., Farre R. Sleep-disordered breathing and cancer mortality: results from the Wisconsin sleep cohort study. Am J Respir Crit Care Med 2012, 186:190-194.
11. Ancoli-Israel S., Klauber M.R., Butters N., Parker L., Kripke D.F. Dementia in institutionalized elderly: relation to sleep apnea. JAm Geriatr Soc 1991, 39:258-263.
12. Ancoli-Israel S., Palmer B.W., Cooke J.R., Corey-Bloom J., Fiorentino L., Natarajan L., et al. Cognitive effects of treating obstructive sleep apnea in Alzheimer's disease: a randomized controlled study. JAm Geriatr Soc 2008, 56:2076-2081.
13. Hoch C.C., Reynolds C.F., Kupfer D.J., Houck P.R., Berman S.R., Stack J.A. Sleep-disordered breathing in normal and pathologic aging. JClin Psychiatry 1986, 47:499-503.
14. Ancoli-Israel S., Coy T. Are breathing disturbances in elderly equivalent to sleep apnea syndrome?. Sleep 1994, 17:77-83.
15. Yaffe K., Laffan A.M., Harrison S.L., Redline S., Spira A.P., Ensrud K.E., et al. Sleep-disordered breathing, hypoxia, and risk of mild cognitive impairment and dementia in older women. JAMA 2011, 306:613-619.
16. Gehrman P.R., Martin J.L., Shochat T., Nolan S., Corey-Bloom J., Ancoli-Israel S. Sleep-disordered breathing and agitation in institutionalized adults with Alzheimer disease. Am J Geriatr Psychiatry 2003, 11:426-433.
17. Nair D., Zhang S.X., Ramesh V., Hakim F., Kaushal N., Wang Y., et al. Sleep fragmentation induces cognitive deficits via nicotinamide adenine dinucleotide phosphate oxidase-dependent pathways in mouse. Am J Respir Crit Care Med 2011, 184:1305-1312.
18. O'Brien L.M., Tauman R., Gozal D. Sleep pressure correlates of cognitive and behavioral morbidity in snoring children. Sleep 2004, 27:279-282.
19. Ramesh V., Nair D., Zhang S.X., Hakim F., Kaushal N., Kayali F., et al. Disrupted sleep without sleep curtailment induces sleepiness and cognitive dysfunction via the tumor necrosis factor-alpha pathway. JNeuroinflammation 2012, 9:91.
20. Ferri R., Drago V., Arico D., Bruni O., Remington R.W., Stamatakis K., et al. The effects of experimental sleep fragmentation on cognitive processing. Sleep Med 2010, 11:378-385.
21. Stamatakis K.A., Punjabi N.M. Effects of sleep fragmentation on glucose metabolism in normal subjects. Chest 2010, 137:95-101.
22. Goldbart A., Row B.W., Kheirandish L., Schurr A., Gozal E., Guo S.Z., et al. Intermittent hypoxic exposure during light phase induces changes in cAMP response element binding protein activity in the rat CA1 hippocampal region: water maze performance correlates. Neuroscience 2003, 122:585-590.
23. Zhu Y., Fenik P., Zhan G., Mazza E., Kelz M., Aston-Jones G., et al. Selective loss of catecholaminergic wake active neurons in a murine sleep apnea model. JNeurosci 2007, 27:10060-10071.
24. Harris K.M. Structure, development, and plasticity of dendritic spines. Curr Opin Neurobiol 1999, 9:343-348.
25. Lee K.F., Soares C., Beique J.C. Examining form and function of dendritic spines. Neural Plast 2012, 2012:704103.
26. Spires-Jones T., Knafo S. Spines, plasticity, and cognition in Alzheimer's model mice. Neural Plast 2012, 2012:319836.
27. Schoch H.J., Fischer S., Marti H.H. Hypoxia-induced vascular endothelial growth factor expression causes vascular leakage in the brain. Brain 2002, 125:2549-2557.
28. Mathiisen T.M., Lehre K.P., Danbolt N.C., Ottersen O.P. The perivascular astroglial sheath provides a complete covering of the brain microvessels: an electron microscopic 3D reconstruction. Glia 2010, 58:1094-1103.
29. Nag S. Morphology and molecular properties of cellular components of normal cerebral vessels. Methods Mol Med 2003, 89:3-36.
30. Utech M., Bruwer M., Nusrat A. Tight junctions and cell-cell interactions. Methods Mol Biol 2006, 341:185-195.
31. Meyle J., Gultig K., Rascher G., Wolburg H. Transepithelial electrical resistance and tight junctions of human gingival keratinocytes. JPeriodontal Res 1999, 34:214-222.
32. Lauwers F., Cassot F., Lauwers-Cances V., Puwanarajah P., Duvernoy H. Morphometry of the human cerebral cortex microcirculation: general characteristics and space-related profiles. Neuroimage 2008, 39:936-948.
33. Hirase T., Staddon J.M., Saitou M., Ando-Akatsuka Y., Itoh M., Furuse M., et al. Occludin as a possible determinant of tight junction permeability in endothelial cells. JCell Sci 1997, 110(Pt 14):1603-1613.
34. Lochhead J.J., McCaffrey G., Quigley C.E., Finch J., DeMarco K.M., Nametz N., et al. Oxidative stress increases blood-brain barrier permeability and induces alterations in occludin during hypoxia-reoxygenation. JCereb Blood Flow Metab 2010, 30:1625-1636.
35. Ohtsuki S., Terasaki T. Contribution of carrier-mediated transport systems to the blood-brain barrier as a supporting and protecting interface for the brain; importance for CNS drug discovery and development. Pharm Res 2007, 24:1745-1758.
36. Armulik A., Genove G., Betsholtz C. Pericytes: developmental, physiological, and pathological perspectives, problems, and promises. Dev Cell 2011, 21:193-215.
37. Chakravarthy U., Gardiner T.A. Endothelium-derived agents in pericyte function/dysfunction. Prog Retin Eye Res 1999, 18:511-527.
38. Harrison R.V., Harel N., Panesar J., Mount R.J. Blood capillary distribution correlates with hemodynamic-based functional imaging in cerebral cortex. Cereb Cortex 2002, 12:225-233.
39. Dore-Duffy P., LaManna J.C. Physiologic angiodynamics in the brain. Antioxid Redox Signal 2007, 9:1363-1371.
40. Dore-Duffy P., Mehedi A., Wang X., Bradley M., Trotter R., Gow A. Immortalized CNS pericytes are quiescent smooth muscle actin-negative and pluripotent. Microvasc Res 2011, 82:18-27.
41. Franco M., Roswall P., Cortez E., Hanahan D., Pietras K. Pericytes promote endothelial cell survival through induction of autocrine VEGF-A signaling and Bcl-w expression. Blood 2011, 118:2906-2917.
42. Dore-Duffy P., Owen C., Balabanov R., Murphy S., Beaumont T., Rafols J.A. Pericyte migration from the vascular wall in response to traumatic brain injury. Microvasc Res 2000, 60:55-69.
43. Bennett M.R., Farnell L., Gibson W.G. Origins of the BOLD changes due to synaptic activity at astrocytes abutting arteriolar smooth muscle. JTheor Biol 2008, 252:123-130.
44. Nag S. Morphology and properties of astrocytes. Methods Mol Biol 2011, 686:69-100.
45. Zlokovic B.V. The blood-brain barrier in health and chronic neurodegenerative disorders. Neuron 2008, 57:178-201.
46. Zador Z., Bloch O., Yao X., Manley G.T. Aquaporins: role in cerebral edema and brain water balance. Prog Brain Res 2007, 161:185-194.
47. Somjen G.G. Ion regulation in the brain: implications for pathophysiology. Neuroscientist 2002, 8:254-267.
48. Simpson I.A., Carruthers A., Vannucci S.J. Supply and demand in cerebral energy metabolism: the role of nutrient transporters. JCereb Blood Flow Metab 2007, 27:1766-1791.
49. Hawkins R.A., O'Kane R.L., Simpson I.A., Vina J.R. Structure of the blood-brain barrier and its role in the transport of amino acids. JNutr 2006, 136:218S-226S.
50. van Vliet E.A., da Costa Araujo S., Redeker S., van Schaik R., Aronica E., Gorter J.A. Blood-brain barrier leakage may lead to progression of temporal lobe epilepsy. Brain 2007, 130:521-534.
51. Gorter J.A., Mesquita A.R., van Vliet E.A., da Silva F.H., Aronica E. Increased expression of ferritin, an iron-storage protein, in specific regions of the parahippocampal cortex of epileptic rats. Epilepsia 2005, 46:1371-1379.
52. Piers T.M., Heales S.J., Pocock J.M. Positive allosteric modulation of metabotropic glutamate receptor 5 down-regulates fibrinogen-activated microglia providing neuronal protection. Neurosci Lett 2011, 505:140-145.
53. van Sorge N.M., Doran K.S. Defense at the border: the blood-brain barrier versus bacterial foreigners. Future Microbiol 2012, 7:383-394.
54. Salinas S., Schiavo G., Kremer E.J. Ahitchhiker's guide to the nervous system: the complex journey of viruses and toxins. Nat Rev Microbiol 2010, 8:645-655.
55. Tamaki A., Ierano C., Szakacs G., Robey R.W., Bates S.E. The controversial role of ABC transporters in clinical oncology. Essays Biochem 2011, 50:209-232.
56. Macdonald N., Gledhill A. Potential impact of ABCB1 (p-glycoprotein) polymorphisms on avermectin toxicity in humans. Arch Toxicol 2007, 81:553-563.
57. Alvarez J.I., Cayrol R., Prat A. Disruption of central nervous system barriers in multiple sclerosis. Biochim Biophys Acta 2011, 1812:252-264.
58. Wang Y., Guo S.Z., Bonen A., Li R.C., Kheirandish-Gozal L., Zhang S.X., et al. Monocarboxylate transporter 2 and stroke severity in a rodent model of sleep apnea. JNeurosci 2011, 31:10241-10248.
59. Yamamoto Y.L., Phillips K.M., Hodge C.P., Feindel W. Microregional blood flow changes in experimental cerebral ischemia. Effects of arterial carbon dioxide studied by fluorescein angiography and xenon 133 clearance. JNeurosurg 1971, 35:155-166.
60. Horovitz S.G., Fukunaga M., de Zwart J.A., van Gelderen P., Fulton S.C., Balkin T.J., et al. Low frequency BOLD fluctuations during resting wakefulness and light sleep: a simultaneous EEG-fMRI study. Hum Brain Mapp 2008, 29:671-682.
61. Fukunaga M., Horovitz S.G., de Zwart J.A., van Gelderen P., Balkin T.J., Braun A.R., et al. Metabolic origin of BOLD signal fluctuations in the absence of stimuli. JCereb Blood Flow Metab 2008, 28:1377-1387.
62. Thomas R.J., Rosen B.R., Stern C.E., Weiss J.W., Kwong K.K. Functional imaging of working memory in obstructive sleep-disordered breathing. JAppl Physiol 2005, 98:2226-2234.
63. Swain R.A., Harris A.B., Wiener E.C., Dutka M.V., Morris H.D., Theien B.E., et al. Prolonged exercise induces angiogenesis and increases cerebral blood volume in primary motor cortex of the rat. Neuroscience 2003, 117:1037-1046.
64. Harik S.I., Hritz M.A., LaManna J.C. Hypoxia-induced brain angiogenesis in the adult rat. JPhysiol 1995, 485(Pt 2):525-530.
65. Mironov V., Hritz M.A., LaManna J.C., Hudetz A.G., Harik S.I. Architectural alterations in rat cerebral microvessels after hypobaric hypoxia. Brain Res 1994, 660:73-80.
66. Stewart P.A., Isaacs H., LaManna J.C., Harik S.I. Ultrastructural concomitants of hypoxia-induced angiogenesis. Acta Neuropathol 1997, 93:579-584.
67. Robbins S.L., Cotran R.S., Kumar V. Pathologic basis of disease 1984, Saunders, Philadelphia. 3rd ed.
68. Carreau A., El Hafny-Rahbi B., Matejuk A., Grillon C., Kieda C. Why is the partial oxygen pressure of human tissues a crucial parameter? Small molecules and hypoxia. JCell Mol Med 2011, 15:1239-1253.
69. Reinke C., Bevans-Fonti S., Drager L.F., Shin M.K., Polotsky V.Y. Effects of different acute hypoxic regimens on tissue oxygen profiles and metabolic outcomes. JAppl Physiol 2011, 111:881-890.
70. Millonig G., Hegedusch S., Becker L., Seitz H.K., Schuppan D., Mueller S. Hypoxia-inducible factor 1 alpha under rapid enzymatic hypoxia: cells sense decrements of oxygen but not hypoxia per se. Free Radic Biol Med 2009, 46:182-191.
71. Wang Y., Zhang S.X., Gozal D. Reactive oxygen species and the brain in sleep apnea. Respir Physiol Neurobiol 2010, 174:307-316.
72. Lavie L. Obstructive sleep apnoea syndrome-an oxidative stress disorder. Sleep Med Rev 2003, 7:35-51.
73. Manukhina E.B., Downey H.F., Mallet R.T. Role of nitric oxide in cardiovascular adaptation to intermittent hypoxia. Exp Biol Med (Maywood) 2006, 231:343-365.
74. Lavie L. Sleep-disordered breathing and cerebrovascular disease: a mechanistic approach. Neurol Clin 2005, 23:1059-1075.
75. Brown M.K., Naidoo N. The UPR and the anti-oxidant response: relevance to sleep and sleep loss. Mol Neurobiol 2010, 42:103-113.
76. Moroz E., Carlin S., Dyomina K., Burke S., Thaler H.T., Blasberg R., et al. Real-time imaging of HIF-1alpha stabilization and degradation. PLoS One 2009, 4:e5077.
77. Semenza G.L., Wang G.L. Anuclear factor induced by hypoxia via de novo protein synthesis binds to the human erythropoietin gene enhancer at a site required for transcriptional activation. Mol Cell Biol 1992, 12:5447-5454.
78. Salceda S., Caro J. Hypoxia-inducible factor 1alpha (HIF-1alpha) protein is rapidly degraded by the ubiquitin-proteasome system under normoxic conditions. Its stabilization by hypoxia depends on redox-induced changes. JBiol Chem 1997, 272:22642-22647.
79. Freeman R.S., Hasbani D.M., Lipscomb E.A., Straub J.A., Xie L. SM-20, EGL-9, and the EGLN family of hypoxia-inducible factor prolyl hydroxylases. Mol Cells 2003, 16:1-12.
80. Maxwell P.H., Wiesener M.S., Chang G.W., Clifford S.C., Vaux E.C., Cockman M.E., et al. The tumour suppressor protein VHL targets hypoxia-inducible factors for oxygen-dependent proteolysis. Nature 1999, 399:271-275.
81. Semenza G.L. Hydroxylation of HIF-1: oxygen sensing at the molecular level. Physiology (Bethesda) 2004, 19:176-182.
82. Xia X., Kung A.L. Preferential binding of HIF-1 to transcriptionally active loci determines cell-type specific response to hypoxia. Genome Biol 2009, 10:R113.
83. Keith B., Johnson R.S., Simon M.C. HIF1alpha and HIF2alpha: sibling rivalry in hypoxic tumour growth and progression. Nat Rev Cancer 2011, 12:9-22.
84. Nanduri J., Wang N., Yuan G., Khan S.A., Souvannakitti D., Peng Y.J., et al. Intermittent hypoxia degrades HIF-2alpha via calpains resulting in oxidative stress: implications for recurrent apnea-induced morbidities. Proc Natl Acad Sci U S A 2009, 106:1199-1204.
85. Lofstedt T., Fredlund E., Holmquist-Mengelbier L., Pietras A., Ovenberger M., Poellinger L., et al. Hypoxia inducible factor-2alpha in cancer. Cell Cycle 2007, 6:919-926.
86. Holmquist-Mengelbier L., Fredlund E., Lofstedt T., Noguera R., Navarro S., Nilsson H., et al. Recruitment of HIF-1alpha and HIF-2alpha to common target genes is differentially regulated in neuroblastoma: HIF-2alpha promotes an aggressive phenotype. Cancer Cell. 2006, 10:413-423.
87. Xu S., Li S., Yang Y., Tan J., Lou H., Jin W., et al. Agenome-wide search for signals of high-altitude adaptation in Tibetans. Mol Biol Evol 2011, 28:1003-1011.
88. Semenza G.L. HIF-1: mediator of physiological and pathophysiological responses to hypoxia. JAppl Physiol 2000, 88:1474-1480.
89. Dayyat E.A., Zhang S.X., Wang Y., Cheng Z.J., Gozal D. Exogenous erythropoietin administration attenuates intermittent hypoxia-induced cognitive deficits in a murine model of sleep apnea. BMC Neurosci 2012, 13:77.
90. Benderro G.F., Lamanna J.C. Hypoxia-induced angiogenesis is delayed in aging mouse brain. Brain Res 2011, 1389:50-60.
91. Skuli N., Liu L., Runge A., Wang T., Yuan L., Patel S., et al. Endothelial deletion of hypoxia-inducible factor-2alpha (HIF-2alpha) alters vascular function and tumor angiogenesis. Blood 2009, 114:469-477.
92. Wiesener M.S., Jurgensen J.S., Rosenberger C., Scholze C.K., Horstrup J.H., Warnecke C., et al. Widespread hypoxia-inducible expression of HIF-2alpha in distinct cell populations of different organs. FASEB J 2003, 17:271-273.
93. Ignacak M.L., Harbaugh S.V., Dayyat E., Row B.W., Gozal D., Czyzyk-Krzeska M.F. Intermittent hypoxia regulates RNA polymerase II in hippocampus and prefrontal cortex. Neuroscience 2009, 158:1436-1445.
94. Yamauchi M., Tamaki S., Tomoda K., Yoshikawa M., Fukuoka A., Makinodan K., et al. Evidence for activation of nuclear factor kappaB in obstructive sleep apnea. Sleep Breath 2006, 10:189-193.
95. Htoo A.K., Greenberg H., Tongia S., Chen G., Henderson T., Wilson D., et al. Activation of nuclear factor kappaB in obstructive sleep apnea: a pathway leading to systemic inflammation. Sleep Breath 2006, 10:43-50.
96. Grammas P. Neurovascular dysfunction, inflammation and endothelial activation: implications for the pathogenesis of Alzheimer's disease. JNeuroinflammation 2011, 8:26.
97. Jurgens H.A., Amancherla K., Johnson R.W. Influenza infection induces neuroinflammation, alters hippocampal neuron morphology, and impairs cognition in adult mice. JNeurosci 2012, 32:3958-3968.
98. Block M.L., Zecca L., Hong J.S. Microglia-mediated neurotoxicity: uncovering the molecular mechanisms. Nat Rev Neurosci 2007, 8:57-69.
99. Milatovic D., Zaja-Milatovic S., Montine K.S., Horner P.J., Montine T.J. Pharmacologic suppression of neuronal oxidative damage and dendritic degeneration following direct activation of glial innate immunity in mouse cerebrum. JNeurochem 2003, 87:1518-1526.
100. Jelic S., Le Jemtel T.H. Inflammation, oxidative stress, and the vascular endothelium in obstructive sleep apnea. Trends Cardiovasc Med 2008, 18:253-260.
101. Drager L.F., Li J., Reinke C., Bevans-Fonti S., Jun J.C., Polotsky V.Y. Intermittent hypoxia exacerbates metabolic effects of diet-induced obesity. Obesity (Silver Spring) 2011, 19:2167-2174.
102. Arnardottir E.S., Maislin G., Schwab R.J., Staley B., Benediktsdottir B., Olafsson I., et al. The interaction of obstructive sleep apnea and obesity on the inflammatory markers C-reactive protein and interleukin-6: the Icelandic sleep apnea cohort. Sleep 2012, 35:921-932.
103. Li R.C., Haribabu B., Mathis S.P., Kim J., Gozal D. Leukotriene B4 receptor-1 mediates intermittent hypoxia-induced atherogenesis. Am J Respir Crit Care Med 2011, 184:124-131.
104. Li R.C., Row B.W., Gozal E., Kheirandish L., Fan Q., Brittian K.R., et al. Cyclooxygenase 2 and intermittent hypoxia-induced spatial deficits in the rat. Am J Respir Crit Care Med 2003, 168:469-475.
105. Choi J.M., Bothwell A.L. The nuclear receptor PPARs as important regulators of T-cell functions and autoimmune diseases. Mol Cells 2012, 33:217-222.
106. Tugwood J.D., Issemann I., Anderson R.G., Bundell K.R., McPheat W.L., Green S. The mouse peroxisome proliferator activated receptor recognizes a response element in the 5' flanking sequence of the rat acyl CoA oxidase gene. EMBO J 1992, 11:433-439.
107. Sharma S., Malur A., Marshall I., Huizar I., Barna B.P., Pories W., et al. Alveolar macrophage activation in obese patients with obstructive sleep apnea. Surgery 2012, 151:107-112.
108. Wu Z., Bucher N.L., Farmer S.R. Induction of peroxisome proliferator-activated receptor gamma during the conversion of 3T3 fibroblasts into adipocytes is mediated by C/EBPbeta, C/EBPdelta, and glucocorticoids. Mol Cell Biol 1996, 16:4128-4136.
109. Bunger M., Hooiveld G.J., Kersten S., Muller M. Exploration of PPAR functions by microarray technology-a paradigm for nutrigenomics. Biochim Biophys Acta 2007, 1771:1046-1064.
110. Guri A.J., Hontecillas R., Bassaganya-Riera J. Peroxisome proliferator-activated receptors: bridging metabolic syndrome with molecular nutrition. Clin Nutr 2006, 25:871-885.
111. Narala V.R., Adapala R.K., Suresh M.V., Brock T.G., Peters-Golden M., Reddy R.C. Leukotriene B4 is a physiologically relevant endogenous peroxisome proliferator-activated receptor-alpha agonist. JBiol Chem 2010, 285:22067-22074.
112. Tiyerili V., Muller C.F., Fung S., Panek D., Nickenig G., Becher U.M. Estrogen improves vascular function via peroxisome-proliferator-activated-receptor-gamma. JMol Cell Cardiol 2012, 53:268-276.
113. Burris T.P., Busby S.A., Griffin P.R. Targeting orphan nuclear receptors for treatment of metabolic diseases and autoimmunity. Chem Biol 2012, 19:51-59.
114. Belanger M., Allaman I., Magistretti P.J. Brain energy metabolism: focus on astrocyte-neuron metabolic cooperation. Cell Metab 2011, 14:724-738.
115. Sokoloff L. The physiological and biochemical bases of functional brain imaging. Cogn Neurodyn 2008, 2:1-5.
116. Lipton P. Ischemic cell death in brain neurons. Physiol Rev 1999, 79:1431-1568.
117. Hermann D.M., Kilic E., Spudich A., Kramer S.D., Wunderli-Allenspach H., Bassetti C.L. Role of drug efflux carriers in the healthy and diseased brain. Ann Neurol 2006, 60:489-498.
118. Pahnke J., Wolkenhauer O., Krohn M., Walker L.C. Clinico-pathologic function of cerebral ABC transporters - implications for the pathogenesis of Alzheimer's disease. Curr Alzheimer Res 2008, 5:396-405.
119. Dopp J.M., Moran J.J., Abel N.J., Wiegert N.A., Cowgill J.B., Olson E.B., et al. Influence of intermittent hypoxia on myocardial and hepatic P-glycoprotein expression in a rodent model. Pharmacotherapy 2009, 29:365-372.
120. Gong S.J., Chen L.Y., Zhang M., Gong J.X., Ma Y.X., Zhang J.M., et al. Intermittent hypobaric hypoxia preconditioning induced brain ischemic tolerance by up-regulating glial glutamate transporter-1 in rats. Neurochem Res 2012, 37:527-537.
121. Baronio D., Martinez D., Fiori C.Z., Bambini-Junior V., Forgiarini L.F., Pase da Rosa D., et al. Altered aquaporins in the brains of mice submitted to intermittent hypoxia model of sleep apnea. Respir Physiol Neurobiol 2012.
122. Wartenberg M., Ling F.C., Muschen M., Klein F., Acker H., Gassmann M., et al. Regulation of the multidrug resistance transporter P-glycoprotein in multicellular tumor spheroids by hypoxia-inducible factor (HIF-1) and reactive oxygen species. FASEB J 2003, 17:503-505.
123. Ji Z., Long H., Hu Y., Qiu X., Chen X., Li Z., et al. Expression of MDR1, HIF-1alpha and MRP1 in sacral chordoma and chordoma cell line CM-319. JExp Clin Cancer Res 2010, 29:158.
124. Ding Z., Yang L., Xie X., Xie F., Pan F., Li J., et al. Expression and significance of hypoxia-inducible factor-1 alpha and MDR1/P-glycoprotein in human colon carcinoma tissue and cells. JCancer Res Clin Oncol 2010, 136:1697-1707.
125. Abreu-Rodriguez I., Sanchez Silva R., Martins A.P., Soveral G., Toledo-Aral J.J., Lopez-Barneo J., et al. Functional and transcriptional induction of aquaporin-1 gene by hypoxia; analysis of promoter and role of Hif-1alpha. PLoS One 2011, 6:e28385.
126. Woo S.K., Kwon M.S., Geng Z., Chen Z., Ivanov A., Bhatta S., et al. Sequential activation of hypoxia-inducible factor 1 and specificity protein 1 is required for hypoxia-induced transcriptional stimulation of Abcc8. JCereb Blood Flow Metab 2012, 32:525-536.
127. Seino S., Miki T. Gene targeting approach to clarification of ion channel function: studies of Kir6.x null mice. JPhysiol 2004, 554:295-300.
128. Martin C.M., Ferdous A., Gallardo T., Humphries C., Sadek H., Caprioli A., et al. Hypoxia-inducible factor-2alpha transactivates Abcg2 and promotes cytoprotection in cardiac side population cells. Circ Res 2008, 102:1075-1081.
129. Yasuda M., Miyazawa M., Fujita M., Kajiwara H., Iida T., Hirasawa T., et al. Expression of hypoxia inducible factor-1alpha (HIF-1alpha) and glucose transporter-1 (GLUT-1) in ovarian adenocarcinomas: difference in hypoxic status depending on histological character. Oncol Rep 2008, 19:111-116.
130. Perez de Heredia F., Wood I.S., Trayhurn P. Hypoxia stimulates lactate release and modulates monocarboxylate transporter (MCT1, MCT2, and MCT4) expression in human adipocytes. Pflugers Arch 2010, 459:509-518.
131. Eisenhofer G., Huynh T.T., Pacak K., Brouwers F.M., Walther M.M., Linehan W.M., et al. Distinct gene expression profiles in norepinephrine- and epinephrine-producing hereditary and sporadic pheochromocytomas: activation of hypoxia-driven angiogenic pathways in von Hippel-Lindau syndrome. Endocr Relat Cancer 2004, 11:897-911.
132. Miwa M., Tsuboi M., Noguchi Y., Enokishima A., Nabeshima T., Hiramatsu M. Effects of betaine on lipopolysaccharide-induced memory impairment in mice and the involvement of GABA transporter 2. JNeuroinflammation 2011, 8:153.
133. Dallas M., Boycott H.E., Atkinson L., Miller A., Boyle J.P., Pearson H.A., et al. Hypoxia suppresses glutamate transport in astrocytes. JNeurosci 2007, 27:3946-3955.
134. Mossner R., Dringen R., Persico A.M., Janetzky B., Okladnova O., Albert D., et al. Increased hippocampal DNA oxidation in serotonin transporter deficient mice. JNeural Transm 2002, 109:557-565.
135. Conrad M., Sato H. The oxidative stress-inducible cystine/glutamate antiporter, system x (c) (-): cystine supplier and beyond. Amino Acids 2012, 42:231-246.
136. Nakaya K., Tohyama J., Naik S.U., Tanigawa H., MacPhee C., Billheimer J.T., et al. Peroxisome proliferator-activated receptor-alpha activation promotes macrophage reverse cholesterol transport through a liver X receptor-dependent pathway. Arterioscler Thromb Vasc Biol 2011, 31:1276-1282.
137. Hoque M.T., Robillard K.R., Bendayan R. Regulation of breast cancer resistant protein by peroxisome proliferator-activated receptor alpha in human brain microvessel endothelial cells. Mol Pharmacol 2012, 81:598-609.
138. Adhikari N., Basi D.L., Carlson M., Mariash A., Hong Z., Lehman U., et al. Increase in GLUT1 in smooth muscle alters vascular contractility and increases inflammation in response to vascular injury. Arterioscler Thromb Vasc Biol 2011, 31:86-94.
139. Pascale C.L., Miller M.C., Chiu C., Boylan M., Caralopoulos I.N., Gonzalez L., et al. Amyloid-beta transporter expression at the blood-CSF barrier is age-dependent. Fluids Barriers CNS 2011, 8:21.
140. Hosoya K., Sugawara M., Asaba H., Terasaki T. Blood-brain barrier produces significant efflux of l-aspartic acid but not d-aspartic acid: invivo evidence using the brain efflux index method. JNeurochem 1999, 73:1206-1211.
141. Tetsuka K., Takanaga H., Ohtsuki S., Hosoya K., Terasaki T. The l-isomer-selective transport of aspartic acid is mediated by ASCT2 at the blood-brain barrier. JNeurochem 2003, 87:891-901.
142. O'Kane R.L., Martinez-Lopez I., DeJoseph M.R., Vina J.R., Hawkins R.A. Na(+)-dependent glutamate transporters (EAAT1, EAAT2, and EAAT3) of the blood-brain barrier. A mechanism for glutamate removal. JBiol Chem 1999, 274:31891-31895.
143. Mori S., Takanaga H., Ohtsuki S., Deguchi T., Kang Y.S., Hosoya K., et al. Rat organic anion transporter 3 (rOAT3) is responsible for brain-to-blood efflux of homovanillic acid at the abluminal membrane of brain capillary endothelial cells. JCereb Blood Flow Metab 2003, 23:432-440.
144. Ohtsuki S., Kikkawa T., Mori S., Hori S., Takanaga H., Otagiri M., et al. Mouse reduced in osteosclerosis transporter functions as an organic anion transporter 3 and is localized at abluminal membrane of blood-brain barrier. JPharmacol Exp Ther 2004, 309:1273-1281.
145. Candela P., Gosselet F., Saint-Pol J., Sevin E., Boucau M.C., Boulanger E., et al. Apical-to-basolateral transport of amyloid-beta peptides through blood-brain barrier cells is mediated by the receptor for advanced glycation end-products and is restricted by P-glycoprotein. JAlzheimers Dis 2010, 22:849-859.
146. Delou J.M., Lopes A.G., Capella M.A. Unveiling the role of multidrug resistance proteins in hypertension. Hypertension 2009, 54:210-216.
147. Janigro D. Are you in or out? Leukocyte, ion, and neurotransmitter permeability across the epileptic blood-brain barrier. Epilepsia 2012, 53(Suppl. 1):26-34.
148. Hackett P.H., Roach R.C. High altitude cerebral edema. High Alt Med Biol 2004, 5:136-146.
149. Wahlin Larsson B., Kadi F., Ulfberg J., Piehl Aulin K. Skeletal muscle morphology and aerobic capacity in patients with obstructive sleep apnoea syndrome. Respiration 2008, 76:21-27.
150. Wahlin-Larsson B., Ulfberg J., Aulin K.P., Kadi F. The expression of vascular endothelial growth factor in skeletal muscle of patients with sleep disorders. Muscle Nerve 2009, 40:556-561.
151. Kanaan A., Farahani R., Douglas R.M., Lamanna J.C., Haddad G.G. Effect of chronic continuous or intermittent hypoxia and reoxygenation on cerebral capillary density and myelination. Am J Physiol Regul Integr Comp Physiol 2006, 290:R1105-R1114.
152. Del Rio R., Munoz C., Arias P., Court F.A., Moya E.A., Iturriaga R. Chronic intermittent hypoxia-induced vascular enlargement and VEGF upregulation in the rat carotid body is not prevented by antioxidant treatment. Am J Physiol Lung Cell Mol Physiol 2011, 301:L702-L711.
153. Jackson J.R., Seed M.P., Kircher C.H., Willoughby D.A., Winkler J.D. The codependence of angiogenesis and chronic inflammation. FASEB J 1997, 11:457-465.
154. Folkman J. Angiogenesis in cancer, vascular, rheumatoid and other disease. Nat Med 1995, 1:27-31.
155. Bikfalvi A., Moenner M., Javerzat S., North S., Hagedorn M. Inhibition of angiogenesis and the angiogenesis/invasion shift. Biochem Soc Trans 2011, 39:1560-1564.
156. Slevin M., Krupinski J. Arole for monomeric C-reactive protein in regulation of angiogenesis, endothelial cell inflammation and thrombus formation in cardiovascular/cerebrovascular disease?. Histol Histopathol 2009, 24:1473-1478.
157. Vagnucci A.H., Li W.W. Alzheimer's disease and angiogenesis. Lancet 2003, 361:605-608.
158. Forsythe J.A., Jiang B.H., Iyer N.V., Agani F., Leung S.W., Koos R.D., et al. Activation of vascular endothelial growth factor gene transcription by hypoxia-inducible factor 1. Mol Cell Biol 1996, 16:4604-4613.
159. Reinke C., Bevans-Fonti S., Grigoryev D.N., Drager L.F., Myers A.C., Wise R.A., et al. Chronic intermittent hypoxia induces lung growth in adult mice. Am J Physiol Lung Cell Mol Physiol 2011, 300:L266-L273.
160. Toffoli S., Roegiers A., Feron O., Van Steenbrugge M., Ninane N., Raes M., et al. Intermittent hypoxia is an angiogenic inducer for endothelial cells: role of HIF-1. Angiogenesis 2009, 12:47-67.
161. Yancopoulos G.D., Davis S., Gale N.W., Rudge J.S., Wiegand S.J., Holash J. Vascular-specific growth factors and blood vessel formation. Nature 2000, 407:242-248.
162. Elson D.A., Thurston G., Huang L.E., Ginzinger D.G., McDonald D.M., Johnson R.S., et al. Induction of hypervascularity without leakage or inflammation in transgenic mice overexpressing hypoxia-inducible factor-1 alpha. Genes Dev 2001, 15:2520-2532.
163. Lavie L., Kraiczi H., Hefetz A., Ghandour H., Perelman A., Hedner J., et al. Plasma vascular endothelial growth factor in sleep apnea syndrome: effects of nasal continuous positive air pressure treatment. Am J Respir Crit Care Med 2002, 165:1624-1628.
164. Gozal D., Lipton A.J., Jones K.L. Circulating vascular endothelial growth factor levels in patients with obstructive sleep apnea. Sleep 2002, 25:59-65.
165. Schulz R., Hummel C., Heinemann S., Seeger W., Grimminger F. Serum levels of vascular endothelial growth factor are elevated in patients with obstructive sleep apnea and severe nighttime hypoxia. Am J Respir Crit Care Med 2002, 165:67-70.
166. Ciftci T.U., Kokturk O., Demirtas S., Gulbahar O., Bukan N. Consequences of hypoxia-reoxygenation phenomena in patients with obstructive sleep apnea syndrome. Ann Saudi Med 2011, 31:14-18.
167. Teramoto S., Kume H., Matsuse T., Ishii T., Miyashita A., Akishita M., et al. Oxygen administration improves the serum level of nitric oxide metabolites in patients with obstructive sleep apnea syndrome. Sleep Med 2003, 4:403-407.
168. Peng Y.J., Yuan G., Ramakrishnan D., Sharma S.D., Bosch-Marce M., Kumar G.K., et al. Heterozygous HIF-1alpha deficiency impairs carotid body-mediated systemic responses and reactive oxygen species generation in mice exposed to intermittent hypoxia. JPhysiol 2006, 577:705-716.
169. Li J., Bosch-Marce M., Nanayakkara A., Savransky V., Fried S.K., Semenza G.L., et al. Altered metabolic responses to intermittent hypoxia in mice with partial deficiency of hypoxia-inducible factor-1alpha. Physiol Genomics 2006, 25:450-457.
170. Diez H., Fischer A., Winkler A., Hu C.J., Hatzopoulos A.K., Breier G., et al. Hypoxia-mediated activation of Dll4-Notch-Hey2 signaling in endothelial progenitor cells and adoption of arterial cell fate. Exp Cell Res 2007, 313:1-9.
171. Skuli N., Majmundar A.J., Krock B.L., Mesquita R.C., Mathew L.K., Quinn Z.L., et al. Endothelial HIF-2alpha regulates murine pathological angiogenesis and revascularization processes. JClin Invest 2012, 122:1427-1443.
172. Feng D., Nagy J.A., Hipp J., Dvorak H.F., Dvorak A.M. Vesiculo-vacuolar organelles and the regulation of venule permeability to macromolecules by vascular permeability factor, histamine, and serotonin. JExp Med 1996, 183:1981-1986.
173. Nagy J.A., Benjamin L., Zeng H., Dvorak A.M., Dvorak H.F. Vascular permeability, vascular hyperpermeability and angiogenesis. Angiogenesis 2008, 11:109-119.
174. Dobrogowska D.H., Lossinsky A.S., Tarnawski M., Vorbrodt A.W. Increased blood-brain barrier permeability and endothelial abnormalities induced by vascular endothelial growth factor. JNeurocytol 1998, 27:163-173.
175. Ruttanaumpawan P., Nopmaneejumruslers C., Logan A.G., Lazarescu A., Qian I., Bradley T.D. Association between refractory hypertension and obstructive sleep apnea. JHypertens 2009, 27:1439-1445.
176. Sitkovsky M., Lukashev D. Regulation of immune cells by local-tissue oxygen tension: HIF1 alpha and adenosine receptors. Nat Rev Immunol 2005, 5:712-721.